About | Contact | Blog | Home


Key Takeaways from FDA’s Draft Guidance on Communications Consistent with Labeling and Memorandum on Off-Label Communications

Tuesday, March 21, 2017 - 1:00PM EST to 2:00PM EST

Learn More

Discover the Performance Coaching Revolution

Thursday March 9, 2017 - 2:00PM EST to 2:40PM EST

Learn More

Do Your Manager’s Really Know How to Help in Accelerating the Sales Process?

Tuesday, March 14, 2017 - 1:00PM EST to 1:30PM EST

Learn More

Medical Affairs Case Study – Generating Real World Evidence for Medical Device Life Cycle Management

Wednesday March 15, 2017 - 1:00PM EST to 2:00PM EST

Learn More

Conducting Successful Device Clinical Trials in China under New Good Clinical Practices (GCP) Guidance

1 Hour Video | Angelina Hao, Normalline 

Purchase Now

The Chinese Food & Drug Administration (CFDA) recently passed medical device clinical trials guidelines which will assist in enhancing the administration and oversight of medical device clinical trials in an effort to focus on GCP compliance, the first such regulation passed in over 12 years. Officially titled “Good Clinical Practice for Medical Devices”, the guidance took effect on June 1, 2016 and included an extensive amended set of Good Clinical Practices for device clinical trials conducted in China, including requirements for multicenter trials, informed consent and record-keeping. Medical device companies looking to conduct clinical trials in China must review current practices and protocols to update standards in accordance with the new GCP guidance.

  • Detailed review of Chinese GCP standards
  • Including new requirements into clinical protocols
  • Outlining related clinical and regulatory developments in China
    • Updated exemption list
    • Site accreditation
  • Time tables and budget considerations for successful trials


Participants that will find this webinar most beneficial will be those involved in medical device companies. Job titles of attendees that will be most applicable for this session will be:

  • Clinical Affairs
  • Clinical Research
  • Regulatory Affairs
  • Quality Assurance



Ms. Angelina Hao is the CEO of Normalline with Master degree of Business Administration (MBA) and Medicine. She has extensive working experiences in Scientific Research and Development in State Research Laboratory, and Production, Quality and Regulatory experience for both American companies and European Companies. With her over 15 years’ experience in R&D management, product transfer, enterprise operation and regulatory management, Angelina co-founded Normalline in 2008, a professional service company to provide Chinese regulatory information, compliance consulting, submission support and relevant management service concentrating on the Medical Devices (MD) and in vitro diagnostics (IVD) industry. The clients are including Johnson&Johnson, Abbott, BD, Medtronic, Boston Scientific, Novartis, Qiagen, Grifols, Alere, Coloplast, STAAR etc. those world-wide known companies. With her extensive experiences and leading management concept in China RA, Angelina is a distinguished expert in Chinese RA and compliance management recognized by the authorities. She is the specially appointed expert by CFDA to train the whole medical device industry since 2010. Normalline was appointed the unique management service company by CMDE (CFDA’s Center for Medical Device Evaluation) to establish the China’s Scientific Evaluation System for Medical Device in 2012.


Q1 Productions
500 N. Dearborn, Suite 500 | Chicago IL 60654 | U.S.
Phone 312 822 8100 | Fax 1 312 602 3834

Copyright 2013 Q1 Productions - All Rights Reserved Privacy Policy

Share This